New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:39 EDTBMRNBioMarin upgraded at Credit Suisse
As previously reported, Credit Suisse upgraded BioMarin to Outperform from Neutral. The firm upgraded shares due to share declines and sees potential catslysts ahead that include BMN 111 Ph I/II results in Q2 2015, BMN 190 and PEG-PAL results in late 2015 and Ph III BMN-701 enrollment in 1H 2015. Price target remains $73.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
09:26 EDTBMRNOn The Fly: Pre-market Movers
Subscribe for More Information
July 30, 2014
16:25 EDTBMRNBioMarin rises after results, first look
Subscribe for More Information
16:24 EDTBMRNBioMarin sells priority review voucher for $67.5M to Regeneron
BioMarin Pharmaceutical (BMRN) announced that it has sold the Rare Pediatric Disease Priority Review Voucher it obtained in February of this year. The company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VIMIZIM, a new biological product for patients with Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. BioMarin received $67.5M from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals (REGN), in exchange for the voucher. "Leveraging the sale of the Priority Review Voucher to reinvest in products to treat rare and ultra-rare diseases makes the most sense for BioMarin given our stage of growth," said Jean-Jacques Bienaimé, CEO of BioMarin.
16:23 EDTBMRNBioMarin raises FY14 revenue view to $745M-$765 from $650M-$680M
Consensus $675.88M. Revenue view includes $67.5M for the sale of the Priority Review Voucher. BioMarin adjusted its view of FY14 non-GAAP net loss to $($60M)-($80M) from ($100)-($130M) previously.
16:18 EDTBMRNBioMarin reports Q2 adjusted EPS 6c, consensus (42c)
Reports Q2 revenue $191.7M, consensus $158.96M. The increased non-GAAP net income for Q2 compared to the second quarter of 2013 was primarily due to strong uptake of VIMIZIM in its first full quarter of commercial sales, and significant growth in revenues from other commercial products including, Naglazyme, KUVAN, Aldurazyme and Firdapse. VIMIZIM sales topped $14M in first full quarter of sales.
15:31 EDTBMRNNotable companies reporting after market close
Subscribe for More Information
July 23, 2014
08:10 EDTBMRNBioMarin, Sarah Cannon Research UK collaborate on EMBRACA clinical study
BioMarin Pharmaceutical and Sarah Cannon Research UK announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation. This ongoing Phase 3 trial has recently been named EMBRACA. Sarah Cannon Research UK enrolled the first patient outside of the United States, expanding the trial internationally.
07:44 EDTBMRNBioMarin survey shows strong Vimizim demand, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use